Acadian Asset Management
RETA

Acadian Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Acadian Asset Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,159
Closed -$287K – 1957
2023
Q1 		$287K Buy
+3,159
New +$185K ﹤0.01% 1185

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management's RETA Position: Q2 2023 in Review

Acadian Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 3,159 shares — an estimated $287K sold.

Acadian Asset Management first reported a position in RETA in Q1 2023 and held it in 1 quarter. The position peaked at $287K in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

  • Acadian Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Acadian Asset Management sold 3,159 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $287K.
  • Acadian Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 1 quarter.
  • Acadian Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $287K in Q1 2023.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Acadian Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.